ERBB2 and breast cancer: Conversely, PI3K/AKT pathway alterations were particularly associated with the poor outcome in HER2+ BC subtypes, underscoring the importance of considering both genetic and hormone receptor/HER2-based subtype context in prognosis and treatment planning.